FDA's Decision-Making Process For ANDA Approval Standards Questioned In Vancomycin Case; Would Process Changes Alter The Outcome?
Executive Summary
ViroPharma has fired another shot across FDA's bow in the continuing battle over approval standards for generic oral vancomycin, charging in a petition supplement that the Office of Generic Drugs' decision to change bioequivalence methods for this antibiotic "was fraught with irregularities.
You may also be interested in...
Lipitor Generics: FDA Says Mylan Has No Standing To Sue (Until June 28?)
FDA is using a recent court decision involving ViroPharma’s antibiotic Vancocin to argue for dismissal of a Mylan Pharmaceuticals Inc. lawsuit that seeks a determination on generic marketing exclusivity rights for Pfizer’s Lipitor.
Lipitor Generics: FDA Says Mylan Has No Standing To Sue (Until June 28?)
FDA is using a recent court decision involving ViroPharma’s antibiotic Vancocin to argue for dismissal of a Mylan Pharmaceuticals Inc. lawsuit that seeks a determination on generic marketing exclusivity rights for Pfizer’s Lipitor.
Follow-On Biologics One Possible Fruit Of FDA-Northeastern Collaboration
A research collaboration agreement between FDA and Northeastern University could help agency officials understand the mechanisms of action of follow-on biologics, thus easing the way for these products once Congress establishes an approval pathway